Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHIF) (FRA:VP2) said that Redesca and Redesca HP, its low molecular weight heparin (LMWH) biosimilar, is now covered for public reimbursement in seven provinces and territories across Canada. That is in addition to several governmental agencies and 70% of privately insured lives for private payer health plans reimbursement.
The pharmaceutical company said it is in advanced discussions for coverage in the remaining provinces.
READ: Valeo Pharma reports record revenue in 2Q, thanks to new product launches
LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than eight years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.
“Reimbursement coverage is always a key component of any commercialization strategy in the healthcare industry, and we are executing according to plan with regards to our Redesca program," said President and Chief Operating Officer Frederic Fasano.
”As one of our three transformative products recently launched, Redesca has already started materially impacting our financial performance,” he added.
Headquartered in Quebec, Valeo Pharma commercialized innovative prescription products in Canada, focusing on respirology, neurodegenerative diseases, oncology, and other specialty products.
Contact the author at stephen.gunnion@proactiveinvestors.com